Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-28
2011-06-28
Solola, Taofiq A (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S404000
Reexamination Certificate
active
07968595
ABSTRACT:
The present invention is directed to a substituted 4H-chromene represented by the Formula 1R, substantially free from the corresponding (S)-stereoisomer:The present invention also relates to the discovery that compound 1R, substantially free from the corresponding (S)-stereoisomer, is an activator of caspases and inducer of apoptosis, as well as an antivascular agent. Therefore, compound 1R, substantially free from the corresponding (S)-stereoisomer, can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs. Compound 1R, substantially free from the corresponding (S)-stereoisomer, also can be used for the treatment of diseases due to overgrowth of vasculature, such as solid tumors and ocular neovascularization.
REFERENCES:
patent: 6858607 (2005-02-01), Cai et al.
patent: 6906203 (2005-06-01), Drewe et al.
patent: 7015328 (2006-03-01), Cai et al.
patent: 7053117 (2006-05-01), Cai et al.
patent: 7135480 (2006-11-01), Cai et al.
patent: 7235674 (2007-06-01), Cai et al.
patent: 2003/0065018 (2003-04-01), Cai et al.
patent: 2005/0154015 (2005-07-01), Drewe et al.
patent: 2005/0165053 (2005-07-01), Cai et al.
patent: 2005/0176750 (2005-08-01), Cai et al.
patent: 2006/0035925 (2006-02-01), Cai et al.
patent: 2006/0104998 (2006-05-01), Cai et al.
patent: WO 01/34591 (2001-05-01), None
patent: WO 02/092076 (2002-11-01), None
patent: WO 02/092594 (2002-11-01), None
patent: WO 2005/046575 (2005-05-01), None
Miller et al, J. Chromatography A, vol. 865 (1999) pp. 211-226.
Karrer, Org. Chem. 2nd Ed. (1946), Elsevier Publishing Co., Inc. NY., 1946, pp. 91-102.
Gourdeau, H., et al., “Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4, 5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents,”Molecular Cancer Therapeutics3:1375-1383, American Association for Cancer Research (2004).
Kasibhatla, S., et al., “Discovery and mechanism of action of a novel series of apoptosis inducers with potential vascular targeting activity,”Molecular Cancer Therapeutics3:1365-1373, American Association for Cancer Research (2004).
Kelland, L.R., Targeting Established Tumor Vasculature: A Novel Approach to Cancer Treatment,Current Cancer Therapy Reviews1:1-9, Bentham Science Publishers Ltd. (2005).
Kemnitzer, W., et al., “Discovery of 4-Ary1-4H-chromenes as a New Series of Apoptosis Inducers Using a Cell- and Caspase-based High-Throughput Screening Assay. 1. Structure-Activity Relationships of the 4-Aryl Group,”J. Med. Chem. 47:6299-6310, American Chemical Society (2004).
Kemnitzer, W., et al., “Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-besed high-throughput screening assay. 2. Structure-activity relationships of the 7- and 5-, 6-, 8-positions,”Bioorganic&Medicinal Chemistry Letters15:4745-4751, Elsevier Science Ltd. (2005).
Kemnitzer, W., et al., “Discovery of 4-Aryl-4H-chromenes as a New Series of Apoptosis Inducers Using a Cell- and Caspase-Based High-Throughput Screening Assay. 3. Structure-Activity Relationships of Fused Rings at the 7,8-Positions,”J. Med. Chem.50:2858-2864, American Chemical Society (2007).
Miller, L., et al., “Preparative chromatographic resolution of enantiomers using polar organic solvents with polysaccharide chiral stationary phases,”Journal of Chromatography A865:211-226, Elsevier Science Ltd (1999).
Nambu, H., et al., “Combretastatin A-4 Phosphate Suppresses Development and Induces Regression of Choroidal Neovascularization,”IOVS44:3650-3655, Association for Research in Vision and Ophthalmology (2003).
Tozer, G.M., et al., “Disrupting Tumour Blood Vessels,”Nature Reviews Cancer5:423-435, Nature Publishing Group (2005).
Vincent, L., et al., “Combretastatin A4 phosphate induces rapid regression of tumor neovessls and growth through interference with vascular endothelial-cadherin signaling,”J. Clin. Invest. 115:2992-3006, American Society for Clinical Investigation (2005).
Office Action for U.S. Appl. No. 11/150,586, Cai, S.X., filed Jun. 13, 2005, mailed on Jan. 18, 2008.
International Search Report for International Application No. PCT/US07/15676, mailed on Jan. 2, 2008, ISA/US, Virginia, United States of America.
Hutchinson, I., et al., “Antitumor Benzothiazoles. 16.1Synthesis and Pharmaceutical Properties of Antitumor 2-(4-Aminophenyl)benzothiazole Amino Acid Prodrugs,”J. Med. Chem. 45:744-747, American Chemical Society, United States (2002).
Supplementary European Search Report for EP Application No. 07810283.7, Munich, Germany, mailed Aug. 18, 2010 (4 pages).
Blais Charles
Cai Sui Xiong
Drewe John A.
Gourdeau Henriette
Kasibhatla Shailaja
Cytovia, Inc.
Solola Taofiq A
Sterne Kessler Goldstein & Fox PLLC
LandOfFree
Substituted 4-aryl-chromene as activator of caspases and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 4-aryl-chromene as activator of caspases and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 4-aryl-chromene as activator of caspases and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2670632